ABK Biomedical Inc., a pioneering medical device company advancing imageable embolic therapies, has secured $35 million in Series D funding to accelerate clinical trials, scale commercialization efforts, and expand its innovative portfolio in interventional radiology. The round was led by J.P. Morgan Life Sciences Private Capital, with participation from F-Prime Capital, Santé Ventures, Eight Roads Ventures, and an undisclosed global medical device company.

This investment positions ABK at the forefront of a fast-growing niche in interventional oncology and embolotherapy, empowering clinicians with unprecedented visualization and control in minimally invasive procedures.

---

Revolutionizing Interventional Radiology

Embolotherapy has long been a cornerstone of treating cancerous tumors and vascular diseases. Yet, one persistent challenge remains: visibility. Traditional embolic materials, while effective at blocking blood flow to tumors, cannot be tracked under imaging once delivered  -  leaving clinicians to estimate placement and effectiveness.

ABK Biomedical’s technology changes that.
The company develops radiopaque embolic microspheres  -  uniquely engineered particles that are visible under X-ray and CT imaging in real-time. This allows interventional radiologists to see exactly where and how embolics are deployed, enhancing safety, precision, and treatment outcomes.

Its flagship products, Eidra™ and Eye90™ microspheres, are being designed to enable better physician control, improved patient outcomes, and clearer post-procedure assessment.

“Visibility changes everything,” says Michael Mangano, CEO of ABK Biomedical. “When you can see what you’re treating, you can deliver therapy with confidence and accuracy that was never before possible.”

---

Bridging Imaging and Therapy  -  A Game-Changing Approach

What sets ABK apart isn’t just innovation  -  it’s integration. The company’s core strategy combines diagnostic imaging and therapeutic intervention into a single workflow, turning previously blind procedures into data-rich, image-guided treatments.

This convergence represents a new class of “theranostic” (therapy + diagnostic) medicine  -  a field expected to reshape oncology and vascular care over the next decade.

By embedding imageability directly into the embolic material, ABK’s platform eliminates guesswork, supports adaptive treatment decisions during procedures, and improves post-procedure monitoring. The result is smarter, safer, and more measurable medicine.

---

A Lesson for Founders: Deep Tech Wins in the Details

One of the most overlooked truths in deep-tech startups is that transformative innovation often comes from mastering the invisible details. ABK’s success underscores this perfectly  -  rather than chasing hype or speed, they’ve built competitive differentiation through micro-level precision and material science.

For founders, the takeaway is powerful: real disruption doesn’t always come from radical reinvention  -  it often comes from solving the industry’s “smallest” unsolved problems that have the biggest downstream impact.

ABK’s decision to tackle the imaging blind spot in embolotherapy  -  something the field tolerated for years  -  is what turned a mature medical process into an entirely new therapeutic paradigm.

In short: when you make the invisible visible, you change the entire system around it.

---

Strategic Investor Support and Industry Validation

ABK Biomedical’s investor consortium reflects deep expertise across both life sciences innovation and medical device commercialization.

• J.P. Morgan Life Sciences Private Capital, the round’s lead investor, has a history of supporting advanced therapeutics and precision medicine ventures.
  
• F-Prime Capital and Eight Roads Ventures, both connected to Fidelity, bring decades of strategic insight into healthcare scale-ups and regulatory navigation.
  
• Santé Ventures, known for backing groundbreaking medtech innovations, reinforces ABK’s credibility within interventional medicine.
  
• The participation of an undisclosed global medical device company further validates ABK’s clinical potential and positions the startup for strategic partnerships and distribution acceleration.
  

This syndicate doesn’t just add capital  -  it provides infrastructure, expertise, and access to a global clinical and regulatory ecosystem that can accelerate ABK’s path to market.

---

Clinical Pipeline and Commercialization Plans

The newly raised funds will support pivotal clinical trials, regulatory submissions, and the company’s expansion into new geographic markets.

• Eye90™ microspheres, designed for radioembolization of liver cancer, are progressing through early feasibility trials in the United States.
  
• Eidra™ microspheres, a purely embolic (non-radioactive) platform, are aimed at treating hypervascular tumors and uterine fibroids with enhanced precision.
  

Together, these products aim to redefine standards of care in oncology and interventional radiology  -  offering physicians real-time feedback and patients better treatment predictability.

The company also plans to grow its U.S. operations and establish new partnerships with leading academic centers to further validate its imageable technology’s clinical impact.

---

The Industry Context: Interventional Radiology on the Rise

The global interventional radiology (IR) market is experiencing remarkable growth, driven by advances in imaging, device miniaturization, and patient demand for minimally invasive procedures.

According to Grand View Research, the global IR market was valued at $28.7 billion in 2023 and is expected to reach $45.2 billion by 2030, growing at a CAGR of 6.8%. The embolotherapy segment  -  including tumor and vascular embolization  -  represents one of the fastest-growing areas, fueled by rising cancer incidence and an increasing shift toward outpatient care.

Yet, despite the growth, procedural visualization has remained a key limitation. ABK’s imageable embolics directly address this bottleneck, allowing interventionalists to plan, execute, and evaluate procedures with data-driven precision.

Moreover, with the expanding role of AI in medical imaging, ABK’s visible embolic materials could serve as critical inputs for AI-assisted diagnostics, paving the way for machine-guided treatment optimization in the near future.

---

A Founder’s Perspective: Precision Meets Purpose

For Michael Mangano, a medtech veteran with decades of leadership experience, ABK’s mission goes beyond product innovation  -  it’s about empowering physicians and improving patient outcomes through meaningful visibility.

“Our team is built around a simple principle: when doctors see better, patients do better,” says Mangano. “This funding gives us the resources to scale that vision globally.”

ABK’s journey from a research concept to a clinical-stage leader exemplifies what’s possible when patient needs and scientific ingenuity align. It’s a story of perseverance, precision, and purpose  -  a reminder that in healthcare, progress happens one clear image at a time.